𝔖 Bobbio Scriptorium
✦   LIBER   ✦

L-asparaginase as a marker of chemotherapy dose modification in children with acute lymphoblastic leukemia

✍ Scribed by Jacques Baillargeon; Anne-Marie Langevin; Margaret Lewis; Paul J. Thomas; Judith Mullins; John Dugan; Brad H. Pollock

Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
85 KB
Volume
104
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A prospective cohort study determining t
A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase : Results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study
✍ Lesley G. Mitchell;; the PARKAA Group πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 221 KB πŸ‘ 1 views

## Abstract ## BACKGROUND Thrombotic events (TEs) are serious secondary complications in children with acute lymphoblastic leukemia (ALL) who receive L‐asparaginase (ASP) therapy; however, the prevalence of TEs has not been established. The primary objective of the Prophylactic Antithrombin Replac

Randomized comparison of moderate-dose m
Randomized comparison of moderate-dose methotrexate infusions to oral methotrexate in children with intermediate risk acute lymphoblastic leukemia: A Childrens Cancer Group study
✍ Lange, Beverly J.; Blatt, Julie; Sather, Harland N.; Meadows, Anna T. πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 559 KB

Methotrexate (MTX) infusions of 500-1,000 mg/m2 over 24 hours may improve survival and prevent relapse in children with acute lymphoblastic leukemia (ALL). Childrens Cancer Group (CCG) Study 139 compared weekly oral methotrexate 20 mg/m2/ week (oral MTX) to MTX 500 mg/m2 infused over 24 hours (IV MT